BioSpace News Archive

Today, Kaiser Permanente began participating in a phase 3 clinical trial to test an investigational vaccine against SARS-CoV-2, the virus causing the current COVID-19 global pandemic.

Elemental Enzymes, a St. Louis biotechnology firm, has obtained the first patent for a natural peptide solution that is field-proven to treat Citrus Greening disease.

AzurRx BioPharma, Inc., a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, issued the following letter to its shareholders and the investment community from James Sapirstein, President and Chief Executive Officer.

Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today reported financial results for its fiscal first quarter ended June 30, 2020. Immunovant ended the quarter with approximately $280.3 million in cash. Financial Highlights for Fiscal First Quarter ended June 30, 2020: R&D Expenses: Research and development expenses decreased by $1.6 mi

ClearPoint Neuro, Inc. announced financial results for its second fiscal quarter and six months ended June 30, 2020.

Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today reported its financial results for the second quarter ended June 30, 2020. Second Quarter 2020 and Recent Business Highlights Announced exclusive license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine and MicroLine in Greater China and South Korea;

NL-201 IND submission anticipated during fourth quarter of 2020 Recent financing raises $71.4M in net proceeds to enable broad NL-201 clinical plan and product pipeline development into 2023 Company to host Conference Call Today, August 12, 2020 at 1:30 p.m. Pacific / 4:30 p.m. Eastern SEATTLE, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients, reports financial results for the three and six months ended June 30, 2

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that company management will participate in the 1-on-1 meetings at the upcoming Needham Virtual Cancer Diagnostics 1x1 Conference on Tuesday, August 18, 2020. About Personalis, Inc. Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more compr

Exactech, a developer and producer of innovative implants, instrumentation and computer-assisted technologies for joint replacement surgery, today announced the naming of Kerem Bolukbasi as its new Chief Financial Officer (CFO). Bolukbasi joins Exactech from TPG Capital where he served as an Operations Executive and was responsible for pro